相似文献
1
Trials (and tribulations) of biocompatible peritoneal dialysis fluids.
Perit Dial Int. 2012 May-Jun;32(3):247-51. doi: 10.3747/pdi.2012.00044.
2
Experimental peritoneal dialysis solutions.
Perit Dial Int. 1993;13 Suppl 2:S98-100.
3
Evidence for Biocompatible Peritoneal Dialysis Solutions.
Contrib Nephrol. 2017;189:91-101. doi: 10.1159/000450690. Epub 2016 Dec 12.
4
How to avoid glucose degradation products in peritoneal dialysis fluids.
Perit Dial Int. 2006 Jul-Aug;26(4):490-7.
5
Biocompatible dialysis fluids for peritoneal dialysis.
Cochrane Database Syst Rev. 2014 Mar 27(3):CD007554. doi: 10.1002/14651858.CD007554.pub2.
6
A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
Perit Dial Int. 2012 May-Jun;32(3):280-91. doi: 10.3747/pdi.2010.00176. Epub 2011 Nov 3.
7
Comparison of peritoneal dialysis solutions.
Nephrol Nurs J. 2004 Sep-Oct;31(5):499-507, 520; quiz 508-9.
8
Clinical advantages of new peritoneal dialysis solutions.
Nephrol Dial Transplant. 2002;17 Suppl 3:16-8. doi: 10.1093/ndt/17.suppl_3.16.
9
Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits).
Int J Artif Organs. 2005 Feb;28(2):177-87. doi: 10.1177/039139880502800215.
10
Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.
Perit Dial Int. 2001;21 Suppl 3:S119-24.
引用本文的文献
1
Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.
Clin Exp Nephrol. 2018 Dec;22(6):1427-1436. doi: 10.1007/s10157-018-1602-2. Epub 2018 Jun 20.
2
Is the Effect of Low-GDP Solutions on Residual Renal Function Mediated by Fluid State? An Enigmatic Question which Still Needs to be Solved.
Perit Dial Int. 2016 May-Jun;36(3):239-42. doi: 10.3747/pdi.2015.00149.
3
The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.
Perit Dial Int. 2012 Sep-Oct;32(5):489-92. doi: 10.3747/pdi.2012.00204.
本文引用的文献
1
Biocompatible dialysis fluids for peritoneal dialysis.
Cochrane Database Syst Rev. 2014 Mar 27(3):CD007554. doi: 10.1002/14651858.CD007554.pub2.
2
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.
3
A new neutral-pH low-GDP peritoneal dialysis fluid.
Perit Dial Int. 2012 Jul-Aug;32(4):444-52. doi: 10.3747/pdi.2011.00072. Epub 2012 Mar 1.
4
A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
Perit Dial Int. 2012 May-Jun;32(3):280-91. doi: 10.3747/pdi.2010.00176. Epub 2011 Nov 3.
5
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.
Kidney Int. 2011 Nov;80(9):986-991. doi: 10.1038/ki.2011.244. Epub 2011 Aug 3.
6
Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
BMC Nephrol. 2010 Sep 16;11:25. doi: 10.1186/1471-2369-11-25.
7
Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
Nephrol Dial Transplant. 2010 Jul;25(7):2288-96. doi: 10.1093/ndt/gfq087. Epub 2010 Mar 1.
8
Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.
Perit Dial Int. 2009 Nov-Dec;29(6):647-55.
9
Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum.
Am J Nephrol. 2010;31(1):58-67. doi: 10.1159/000256658. Epub 2009 Nov 4.
10
Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.
Am J Kidney Dis. 2009 Oct;54(4):711-20. doi: 10.1053/j.ajkd.2009.05.014. Epub 2009 Jul 19.
Zotero 插件